Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Xencor, Inc.
Children's Oncology Group
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Loma Linda University
Wake Forest University Health Sciences
Seattle Children's Hospital
Indiana University
Assistance Publique - Hôpitaux de Paris
St. Jude Children's Research Hospital
Children's Oncology Group
Nationwide Children's Hospital
Sun Yat-sen University
Heinrich-Heine University, Duesseldorf
Baylor College of Medicine
National Cancer Institute, Slovakia
N.N. Petrov National Medical Research Center of Oncology
Turning Point Therapeutics, Inc.
University of Sydney
Gustave Roussy, Cancer Campus, Grand Paris
Indiana University